Libido

Lindora Recognizes Men’s Health Month with Complimentary Testosterone Replacement Therapy (TRT) Exams and Labs

Retrieved on: 
星期五, 五月 31, 2024
Other Consumer, Vitamins, Supplements, Fitness & Nutrition, Men, Other Health, Alternative Medicine, General Health, Pharmaceutical, Consumer, Health, Spouse, Metabolism, Libido, Friends, Male, Testosterone, Facial muscles, TRT, Multimedia, Quality of life, Nursing

The National Institute of Health estimates that 50% of men over the age of 80 are hypogonadal, meaning their bodies do not produce enough testosterone.

Key Points: 
  • The National Institute of Health estimates that 50% of men over the age of 80 are hypogonadal, meaning their bodies do not produce enough testosterone.
  • Testosterone levels begin to decline in men starting around the age of 30, so Testosterone Replacement Therapy (TRT) can offer a viable solution to replenish this essential hormone.
  • It can involve replacing testosterone that the body is no longer producing adequately due to the natural aging process or other medical conditions.
  • To know if a consultation and potentially TRT are right for a member, some of the symptoms of low testosterone include:

Dr. Mary Jane Minkin, OB-GYN, Highlights Key Topics Addressed in Annual Visits for Women’s Health Month

Retrieved on: 
星期三, 五月 29, 2024
Oncology, Health, Consumer, Women, Other Health, General Health, Intrauterine device, Patient, Hot, Hormone replacement therapy, Libido, HPV, Education, Cramp, Pleasure, Pregnancy, Anxiety, Cervical cancer, Bacteria, Breast cancer, Vagina, Infection, Vaginitis, PAP, Birth, Yale School of Medicine, MAP, Woman, Menstruation, Reproductive Sciences, Menopause, Personal lubricant, Pain, HRT, Quality of life, Condom, STI, Senior counsel, Birth control

, OB-GYN, Clinical Professor of Obstetrics, Gynecology, and Reproductive Sciences at Yale University School of Medicine, is shedding light on frequently discussed topics during annual OB-GYN visits.

Key Points: 
  • , OB-GYN, Clinical Professor of Obstetrics, Gynecology, and Reproductive Sciences at Yale University School of Medicine, is shedding light on frequently discussed topics during annual OB-GYN visits.
  • Dr. Minkin, dedicated to women's health and education, emphasizes the importance of these routine check-ups for maintaining overall well-being.
  • “Annual appointments with your OB-GYN are essential for early detection of potential issues, such as cervical or breast cancer, menopause and for managing reproductive health.
  • Annual visits are crucial for routine screenings and preventive care, including Pap smears for cervical cancer, mammograms for breast cancer detection, and HPV vaccinations.

Global Hormone Replacement Therapy (HRT) Market Analysis 2024-2032 Featuring Abbott, Bayer, Eli Lilly & Co, Novartis, Novo Nordisk, Pfizer, Abbvie, Teva, Dr. Reddy's Laboratories - ResearchAndMarkets.com

Retrieved on: 
星期三, 五月 29, 2024
Health, Pharmaceutical, Statistics, New Drug Application, Patient, Hot, Hormone replacement therapy, Prescription, Hormone, Ministry, Libido, Arena Pharmaceuticals, Akorn, MHLW, Disorder, Prevalence, FDA, American Thyroid Association, Economic development, Testosterone, Osteoporosis, Dermatology, Gastroenterology, Thyroid, Fertilisation, Cardiology, VMS, Incidence, Acquisition, Insight, Woman, NIH, Tablet, Data science, Menopause, HRT, Fezolinetant, Alfa, Pharmaceutical industry

The global Hormone Replacement Therapy market is projected to attain a value of US$ 35.86 Billion by 2032.

Key Points: 
  • The global Hormone Replacement Therapy market is projected to attain a value of US$ 35.86 Billion by 2032.
  • Ascendis Pharma A/S's drug SKYTROFA received market authorization in January 2022 for treating growth hormone disorders in children and adolescents.
  • The prevalence of hormonal imbalances and related disorders is increasing, leading to a rise in demand for hormone replacement therapy.
  • The US has the biggest market for Hormone Replacement Therapy, with rising utilization among patients over 35 years old.

Nika Pharmaceuticals, Inc. (NKPH) Purchased the Technologies for Three Drugs in Tablet Form and One Dietary Supplement

Retrieved on: 
星期一, 四月 15, 2024
Sale, Brain, Pain, Myalgia, Stroke, Woman, Tissue, Dietary supplement, Infertility, Infection, Testosterone, DSM-IV codes, Pelvic floor dysfunction, Male, Climacteric, Insomnia, System, Dementia, Dysmenorrhea, Erectile dysfunction, Lipid, Anxiety, Toothache, Oxygen, Headache, Acquisition, Memory, Libido, Tribulus terrestris, Tracheobronchitis, Fever, Metamizole

HENDERSON, Nev., April 15, 2024 (GLOBE NEWSWIRE) -- Nika Pharmaceuticals, Inc. (OTCMKTS: NKPH) announces the purchase of four technologies for production of three generic drugs in tablet form and one dietary supplement.

Key Points: 
  • HENDERSON, Nev., April 15, 2024 (GLOBE NEWSWIRE) -- Nika Pharmaceuticals, Inc. (OTCMKTS: NKPH) announces the purchase of four technologies for production of three generic drugs in tablet form and one dietary supplement.
  • The acquisition includes full dossiers for each product, which will allow NKPH to quickly register them for sale once the company has finalized the branding of each.
  • The technologies, which were purchased through NKPH’s subsidiary, Nika Europe Ltd., have a proven market track record, as each of them satisfy an important health need of the population.
  • MENTHYL VALERATE 60mg is an over-the-counter drug with a positive effect on the central nervous and cardiovascular systems.

Rosy Debuts New Content Focused on Menopause and Migraine Education

Retrieved on: 
星期四, 四月 18, 2024
Physician, Webby, PCOS, Woman, Health, MD, Endometriosis, Webby Awards, Migraine, Female, Sensation, Patient, Diagnosis, OB, Libido, Personal lubricant, Quality of life, Menopause, Knowledge, Disability, Birth control

DALLAS, April 18, 2024 /PRNewswire-PRWeb/ -- Rosy, the Webby Award winning app-based platform that addresses common health concerns for women throughout their lifespans, announces an expanded focus beyond sexual wellness. Through its new sponsorship from Pfizer, one of the world's premier biopharmaceutical companies, Rosy will provide women in the U.S. with free evidence-based resources, rolled out in two phases. The first will focus on menopause and the second on migraine, with the overall goal of empowering women to take their health into their own hands.

Key Points: 
  • The first will focus on menopause and the second on migraine, with the overall goal of empowering women to take their health into their own hands.
  • When signing up for Rosy, each user takes a comprehensive Wellness Quiz, allowing Rosy to personalize an evidence-based, CBT-informed program with their unique concerns and priorities in mind.
  • While initially focused on sexual wellness, Rosy has expanded to include a wider range of women's health concerns, including endometriosis, PCOS, and more.
  • Physicians, providers, and hospital systems interested in recommending Rosy to their female patients are welcome to email [email protected] .

MysteryVibe partners with Havas Lynx and makes history by showcasing the very first sex toy on billboards in the U.S.

Retrieved on: 
星期一, 三月 25, 2024
Lynx, Lubrication, FSA, Health, Partnership, Genetics, SVP, Libido, MysteryVibe, History, Menopause, Masturbation, Fertility, Atrophy, Woman, Pleasure, Women's History Month, Sensation, OOH, Stigma, Orgasm, Personal lubricant, HSA, FDA, Women's health, Birth control

The billboard is the first of its kind, making history in sexual wellness advertising by showcasing a visible sex toy in Central Manhattan.

Key Points: 
  • The billboard is the first of its kind, making history in sexual wellness advertising by showcasing a visible sex toy in Central Manhattan.
  • "We are incredibly lucky to have been a part of many 'firsts' in women's health over the past decade," shared Soumyadip Rakshit, CEO and cofounder, MysteryVibe.
  • "Not only are we honored to support a campaign that enables women to overcome taboos around menopause, we know that discomfort shouldn't be normalized."
  • In conjunction with the billboard, the campaign contains other educational elements backed by award-winning reproductive scientist Professor Joyce Harper .

KINDRA LAUNCHES FIRST-EVER COMPREHENSIVE VAGINAL HEALTH SYSTEM: THE DAILY V SYSTEM

Retrieved on: 
星期一, 三月 25, 2024
DPT, Testosterone, Sulfate, Urology, Hormone, Hyaluronic acid, Woman, Vaginal lubrication, FACOG, Libido, Arousal, Paraben, Dry, MD, Itch, Vaginitis, WCS, Skin, Pelvic floor, Stinger, Irritation, Medicine, Personal lubricant, Pain, BCB-PMD, Orgasm, Birth control

NEW YORK, March 25, 2024 /PRNewswire/ -- Today, Kindra, the sex-positive vaginal health brand, announced the launch of the first-ever comprehensive vaginal health product system - the Daily V System. The 4-part daily regimen of Kindra products includes: Daily Vaginal Lotion, V Relief Serum, Soothe Bath Soak and the Core Supplement meant to support vulvar and vaginal skin for optimal vaginal health and sexual wellness.

Key Points: 
  • NEW YORK, March 25, 2024 /PRNewswire/ -- Today, Kindra , the sex-positive vaginal health brand, announced the launch of the first-ever comprehensive vaginal health product system - the Daily V System .
  • The 4-part daily regimen of Kindra products includes: Daily Vaginal Lotion , V Relief Serum , Soothe Bath Soak and the Core Supplement meant to support vulvar and vaginal skin for optimal vaginal health and sexual wellness.
  • This hormone-free system is designed to provide targeted relief and support for daily vulvar and vaginal health needs.
  • As part of its launch of the Daily V System, Kindra has partnered with pelvic floor physical therapist Dr. Sara Reardon, known online as The Vagina Whisperer, on a video about the importance of a daily vaginal health regimen for long-term vulvovaginal health and comfort.

Mastering The Meno(Pause) Transition Summit 3.0: A New Dawn in Women's Health

Retrieved on: 
星期五, 二月 23, 2024
Breast cancer, Pause, Woman, MD, Ageing, Growth, Empowerment, Life, Transition, Health, Menopause, Fatigue, Rejuvenation, Knowledge, Libido, Interview, Birth control

CARLSBAD, Calif., Feb. 23, 2024 /PRNewswire/ -- DrTalks, a leading platform dedicated to advancing health, wellness, and medicine knowledge, is proud to announce the Mastering the Meno(Pause) Transition Summit 3.0. This groundbreaking virtual event aims to redefine societal perceptions of menopause from a phase of apprehension to a period of empowerment and well-being.

Key Points: 
  • Gain practical insights into balancing hormones, managing stress, enhancing libido, and combating fatigue, all designed to facilitate a fulfilling menopausal transition.
  • CARLSBAD, Calif., Feb. 23, 2024 /PRNewswire/ -- DrTalks , a leading platform dedicated to advancing health, wellness, and medicine knowledge, is proud to announce the Mastering the Meno(Pause) Transition Summit 3.0 .
  • The event will feature various topics, including balancing hormones, managing stress, enhancing libido, and combating fatigue, all designed to facilitate a fulfilling menopausal transition.
  • The Mastering the Meno(Pause) Transition Summit 3.0 is more than just an event.

"I Love Fruit & Veg from Europe": healthy eating and passion with a vegetarian Valentine's Day

Retrieved on: 
星期二, 二月 13, 2024
Olive oil, European Commission, Vegetable, Light, Civil service commission, Lycopene, Female, Libido, Male, Basil, Testosterone, Organization, Fruit

LONDON, Feb. 13, 2024 /PRNewswire/ -- Valentine's Day dinner made with fruit and vegetables seasoned with passion. The "I Love Fruit & Veg from Europe" campaign proposes seasonal produce for a romantic vegetarian meal, because light and digestible can be a delicious alternative.

Key Points: 
  • On this healthy lovers' menu: caprese salad, spaghetti with broccoli, ricotta and pecorino and heart-shaped lemon biscuits.
  • LONDON, Feb. 13, 2024 /PRNewswire/ -- Valentine's Day dinner made with fruit and vegetables seasoned with passion.
  • The "I Love Fruit & Veg from Europe" campaign proposes seasonal produce for a romantic vegetarian meal, because light and digestible can be a delicious alternative.
  • Cut the mozzarella into a heart shapes, place on slices of tomato and season with basil, olive oil and salt.

YourChoice Therapeutics begins first-in-human trial for male birth control pill

Retrieved on: 
星期三, 十二月 13, 2023
Biotechnology, Pharmaceutical, Men, Health, Baby, Maternity, Consumer, Clinical Trials, Other Health, Quotient, Woman, Health equity, Research, Condom, Hormone, Testosterone, Safety, Therapy, Risk, Cardiovascular disease, Mouse, Pregnancy, Vitamin A, Vasectomy, Male, Pharmacokinetics, Weight gain, Infertility, Birth, Testicle, University, Trial of the century, Development, Aggression, Bangladesh Technical Education Board, Rat, Libido, Volunteering, Acne, Birth control, Pharmacy

YourChoice Therapeutics, Inc., a pioneer of hormone-free family planning products, began dosing male volunteers in a phase one clinical study of YCT-529, a drug candidate designed to offer the first hormone-free male birth control pill.

Key Points: 
  • YourChoice Therapeutics, Inc., a pioneer of hormone-free family planning products, began dosing male volunteers in a phase one clinical study of YCT-529, a drug candidate designed to offer the first hormone-free male birth control pill.
  • While a male birth control pill has been a vision for decades, current drug candidates in clinical development use hormonal agents that suppress testosterone to prevent sperm production.
  • We thank our investors and the male volunteers who have stepped forward to be a part of this mission.”
    The Male Contraceptive Initiative has contributed generous funding to the development of the first hormone-free male birth control pill since its inception.
  • The first human study for a hormone-free male birth control pill is a long-awaited milestone and a landmark achievement in the quest for reproductive autonomy.